Page 17 - Cost Plus News Today

San Leandro, CA (PRWEB) October 18, 2022 -- VIVIO, a public benefit corporation reinventing the use of drug trial data in care delivery, announces a

SCPH's lead drug candidate FUROSCIX was approved on October 10th by the FDA. To help distribute the drug, SCPH secured a $100 million loan. Read more here.

After earning his doctorate and a medical degree, Dr. Alex Oshmyansky set off on a seemingly impossible quest: disrupt the pharmaceutical industry. Along the way, he was joined by a billionaire maverick. Meet the Mark Cuban Cost Plus Drug Company.

It is Mark Cuban Cost Plus Drug Company's first collaboration with a health plan. The pharmacy company will not be replacing Capital Blue Cross' existing pharmacy benefits manger, but instead will be an additional option for members to choose.

/PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) announced that it has acquired five market-approved anti-cancer drugs approved for...

/PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) announced that it has acquired five market-approved anti-cancer drugs approved for...

/PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists...

"We get people coming to us and saying 'your price is $10, my co-pay is $20,'" said Cuban. "'So I'm ignoring my insurance and coming straight to you.'"

Rightway’s PBM grants its members direct access to all medications available through Mark Cuban Cost Plus Drugs.

Rising U.K. COVID-19 cases may foreshadow U.S. fate; Private equity firms slam Advanz’s £100 million pricing fine.